Global Cancer Diagnostics Patent Reports.pptx

The global cancer diagnostics market was valued at USD 61.50 billion in 2024 and is anticipated to grow at a CAGR of 13.60% during the forecast period from 2025 to 2034, reaching approximately USD 220.12 billion by 2034. This robust growth is driven by the increasing adoption of advanced diagnostic technologies and ongoing innovation in the field. The rising global burden of cancer has led to a significant increase in patent applications, as healthcare providers seek accurate, early detection tools to support timely diagnosis and personalized treatment strategies.

1. Global Cancer Diagnostics Patent Landscape Report & Forecast 2025 Report & Forecast 2025

2. About Claight Claight Corporation is the literal incorporation of clarity and insights. We have one principal objective for our clients- Growth! With our robust plan of action, a team of seasoned insight analysts, and experienced consultants, we deliver Success! Dedicated Team: 400+ Our team, with its diverse backgrounds and expertise, is dedicated to providing clients with high-quality, actionable insights. Competent Experts: 3000+ Our panel of consultants know where you are exactly stuck and what should be the right strategy for you to get that pull-back off your back! Industry Reports: 10000+ Our reports are fueled by vast databases covering an array of industries. We provide insights backed by the latest, most relevant data. Industry Domains: 15+ With our deep-rooted expertise and extensive experience, we craft market research solutions specifically designed for your industry's needs.

3. The cancer diagnostics market was valued at USD 61.50 billion in 2024 and is projected to reach USD 194.54 billion by 2032, growing at a CAGR of 13.6% from 2025 to 2034, driven by rising adoption and continuous technological advancements. Global Cancer Diagnostics Patent Landscape

4. Cancer Diagnostics Patent Landscape Growth Drivers 05 01 This is a sample text. Trade Data Analysis Increasing Technological Innovation in Cancer Diagnosis Expert Market Research delivers the latest data on the Cancer Diagnostics . The ongoing advancement in diagnostic imaging, molecular biology, and genomic profiling has sparked a wave of innovation in cancer diagnostics. Technologies such as next-generation sequencing (NGS) , liquid biopsies , AI-powered imaging , and multi-omics platforms have accelerated the discovery of more accurate and less invasive diagnostic methods. These developments have led to a surge in patent applications aimed at protecting new techniques and diagnostic tools, influencing the overall patent landscape. Emerging technologies are enabling real-time detection of tumor markers and circulating tumor DNA ( ctDNA ), opening new frontiers in cancer detection and patient monitoring. 2. Rising Demand for Personalized Medicine The push towards personalized or precision medicine—tailoring treatments based on individual genetic and molecular profiles—is another key driver shaping the patent landscape. Cancer diagnostics play a central role in identifying specific mutations, biomarkers, and therapeutic targets, thereby guiding treatment decisions. The demand for companion diagnostics, which are co-developed with drugs to determine patient eligibility, has resulted in a sharp rise in patent activity. Companies and institutions are seeking IP protection for unique biomarker discoveries, diagnostic algorithms, and molecular testing platforms that support individualized treatment approaches.

5. Cancer Diagnostics Patent Landscape Segmentation Analysis 05 This is a sample text. Trade Data Analysis Patents related to cancer diagnostics can be segmented based on the underlying technologies. Below is a detailed breakdown: Positron Emission Tomography (PET) PET uses radioactive tracers to assess tissue metabolism and is widely applied in cancer staging and recurrence monitoring. The technology leads in patent filings due to its high sensitivity and ability to provide biological insights beyond anatomical imaging. Computed Tomography (CT) CT remains a cornerstone for structural imaging of tumors. Innovations in low-dose imaging, image reconstruction algorithms, and contrast enhancements have contributed to a steady stream of patents. Multi-parameter Flow Cytometry Extensively used for blood cancers, patents in this area revolve around innovations in antibody panels, laser technologies, and data analytics. Immunohistochemistry (IHC) A key technique for detecting protein markers in tissues, IHC-related patents often involve new antibodies, automated platforms, and multiplexing capabilities. Microarray Patents in this domain cover innovations in gene expression profiling, biomarker discovery, and hybridization methods for cancer diagnostics. Next Generation Sequencing (NGS) NGS is one of the fastest-growing areas in cancer diagnostics patents. Key innovations include targeted panels, sequencing workflows, bioinformatics pipelines, and error-correction technologies that enhance mutation detection.

6. Cancer Diagnostics Patent Landscape Jurisdiction Analysis 05 This is a sample text. Trade Data Analysis United States The U.S. holds the largest share of global cancer diagnostics patents, with around 310,000 active patents . This dominance stems from a mature IP ecosystem, strong R&D investment, and leading academic and industry research centers. Areas such as AI integration in imaging, ctDNA detection, and bioinformatics tools have witnessed extensive patent filings. The FDA’s support for innovation in diagnostics also contributes to a thriving patent environment. China China has emerged as a major jurisdiction, with exponential growth in patent filings over the last five years. Driven by national policies supporting biotech innovation, local companies and research institutes are filing patents in technologies like novel contrast agents , nanotechnology-based probes , and AI-powered diagnostics . China’s growing healthcare infrastructure and massive population provide a fertile ground for both research and commercialization, making it a key player in the global patent landscape. Other notable jurisdictions include the European Union , Japan , and South Korea , each contributing to specialized areas of diagnostic development and patent activity.

7. Cancer Diagnostics Patent Landscape Segmentation 05 01 This is a sample text. Trade Data Analysis Analysis by Product Solid Microneedles  Silicon  Metal   Polymer  Hollow Microneedles  Dissolving Microneedles  Hydrogel  Coated Geographies Covered North America Europe Asia Pacific Others 01 Trade Data Analysis Capacity Additions, Plant Turnarounds and Mergers Competitive Landscape Cost Analysis Demand Drivers Market Trade Data Analysis Additional Insights

8. Leading Companies in the Cancer Diagnostics Patent Landscape Segmentation New entrants, including both established firms and startups developing their first cancer diagnostics technologies, have been identified. Key companies featured in this report include (but are not limited to): F. Hoffmann-La Roche Ltd Roche is a global leader in oncology diagnostics, with a significant patent portfolio in molecular diagnostics and personalized medicine. Through its subsidiary, Roche Diagnostics , the company develops assays for biomarker detection and companion diagnostics, particularly in breast, lung, and colorectal cancers. Roche’s patent filings emphasize innovations in PCR, NGS, and immunohistochemistry. Abbott Abbott focuses heavily on diagnostics, with patents covering liquid biopsy , molecular assays , and tumor marker panels . Its Alinity and m2000 platforms offer integrated diagnostics with high-throughput capabilities. Abbott continues to invest in R&D, with a growing IP portfolio related to cancer genomics and early detection tools. GE HealthCare Technologies Inc. A key player in diagnostic imaging, GE HealthCare has an extensive patent portfolio in CT , PET , and MRI technologies . The company leads in innovations related to image enhancement algorithms, contrast agent development, and AI-based diagnostic platforms, all aimed at improving cancer detection accuracy and speed.

9. Leading Companies in the Cancer Diagnostics Patent Landscape Segmentation Qiagen N.V. Qiagen is prominent in the molecular diagnostics field, especially in biomarker testing , sample preparation , and PCR-based assays . The company’s patents largely relate to companion diagnostics for targeted therapies and genetic mutation detection. Qiagen collaborates with pharma companies to co-develop diagnostics tailored to novel cancer drugs. Becton Dickinson (BD) BD is renowned for its flow cytometry and tissue diagnostics solutions. It holds numerous patents for cytometric techniques, cell analysis software, and antibody technologies. BD’s innovations support the diagnosis of hematologic malignancies and are integrated into advanced diagnostic workflows across hospitals and labs globally.

10. Table of Contents 01 Introduction 02 Executive Summary 03 Global Cancer Diagnostics Market Overview 3.1 Global Cancer Diagnostics Market Historical Value (2018-2024) 3.2 Global Cancer Diagnostics Market Forecast Value (2025-2034) 04 Global Cancer Diagnostics Market Segmentation 4.1 Global Cancer Diagnostics Market Share by Product 4.1.1 Market Overview 4.1.2 Consumables 4.1.2.1 Antibodies 4.1.2.2 Reagents 4.1.2.3 Probes 4.1.2.4 Others 4.1.3 Instrument 4.1.3.1 Pathology Instrument 4.1.3.2 Imaging Instrument 4.1.3.3 Others

11. Table of Contents 4.2 Global Cancer Diagnostics Market Share by Indication 4.2.1 Market Overview 4.2.2 Breast Cancer 4.2.3 Lung Cancer 4.2.4 Colorectal Cancer 4.2.5 Brain Tumor 4.2.6 Blood Cancer 4.2.7 Others 4.3 Global Cancer Diagnostics Market Share by End User 4.3.1 Market Overview 4.3.2 Hospital 4.3.3 Diagnostic Laboratory 4.3.4 Research Centre 05 Global Market Dynamics 5.1 Market Drivers and Constraints 5.2 Porter’s Five Forces Analysis 5.3 PESTEL Analysis

12. Table of Contents 5.4 Industry Events, Initiatives, and Trends 5.5 Value Chain Analysis 06 Global Cancer Diagnostics Patent Landscape Analysis 6.1 Patent Distribution by Publication Year 6.2 Patent Distribution by Application Year 6.3 Patent Distribution by Priority Year 6.4 Analysis by Type of Patent 6.4.1 Granted Patents 6.4.2 Patent Application 6.4.3 Amended Application 6.4.4 Search Report 6.5 Analysis by Legal Status 6.5.1 Active 6.5.2 Pending 6.5.3 Expired/Discontinued 6.6 Analysis by Patent Jurisdiction 6.7 Analysis by Patent Age

13. Table of Contents 6.8 Analysis by Cooperative Patent Classification (CPC) Codes 6.9 Average Time to Publish a Patent 6.9.1 By Entities 6.9.2 By Jurisdiction 6.9.3 By Technology 6.10 Analysis by Type of Entity (Academic and Non-Academic) 6.11 Analysis by Top Applicants 6.12 Analysis by Top Inventors 07 Global Cancer Diagnostics Patent Analysis by Technology 7.1 Total Patents by Top Technologies 7.2 Time Evolution of Patents by Technology 7.3 Emerging Technologies 7.4 Medical imaging 7.4.1 Time Evolution by Number of Patents 7.4.2 Time Evolution by Number of Patent Families 7.4.3 Analysis by Type of Entity (Academic vs Non-Academic) 7.4.4 Analysis by Top Applicants

14. Table of Contents 7.4.5 Analysis by Top Inventors 7.5 AI-based tool 7.5.1 Time Evolution by Number of Patents 7.5.2 Time Evolution by Number of Patent Families 7.5.3 Analysis by Type of Entity (Academic vs Non-Academic) 7.5.4 Analysis by Top Applicants 7.5.5 Analysis by Top Inventors 7.6 Lab-on-chip 7.6.1 Time Evolution by Number of Patents 7.6.2 Time Evolution by Number of Patent Families 7.6.3 Analysis by Type of Entity (Academic vs Non-Academic) 7.6.4 Analysis by Top Applicants 7.6.5 Analysis by Top Inventors 7.7 Liquid biopsy 7.7.1 Time Evolution by Number of Patents 7.7.2 Time Evolution by Number of Patent Families 7.7.3 Analysis by Type of Entity (Academic vs Non-Academic)

15. Table of Contents 7.7.4 Analysis by Top Applicants 7.7.5 Analysis by Top Inventors 08 EMR Patent Valuation Analysis 8.1 Assessment Methodology 8.2 High Value Patents 8.3 Medium Value Patents 8.4 Low Value Patents 09 Global Cancer Diagnostics – Top 10 Players Patent Analysis 9.1 Top 10 Entities by Number of Patents 9.2 Analysis by Publication Year 9.3 Analysis by Application Year 9.4 Analysis by Priority Year 9.5 Analysis by Type of Patent 9.6 Analysis by Jurisdiction 9.7 Analysis by Cooperative Patent Classification (CPC) Codes 9.8 Analysis by Source of Innovation 9.9 Analysis by Forward and Backward Citations

16. Table of Contents 9.10 Analysis by Legal Status 9.11 Analysis by Patent Age 9.12 Analysis by Key Inventors 9.13 Entity Dynamics 9.13.1 Analysis by Type of Player (Academic vs Non-Academic) 9.13.2 Analysis by Collaboration 9.13.3 Analysis by Technology 9.13.4 Newcomers 9.13.4.1 Start-up Companies 9.13.4.2 Established Companies 10 Patent Profile of Key Players 10.1 GE HealthCare Technologies, Inc . 10.1.1 Product Portfolio 10.1.2 Patent Portfolio by Patent Families 10.1.3 Time Evolution of Patents 10.1.4 Geographical Patent Coverage 10.1.5 Patent Analysis by Technology

17. Table of Contents 10.1.6 Patent News and Developments 10.1.7 Financial Analysis 10.1.8 SWOT Analysis 10.2 Abbott Laboratories 10.3 F. Hoffmann-La Roche Ltd 10.4 Qiagen N.V . 10.5 Becton Dickinson & Company 11 Future Trends 12 Global Cancer Diagnostics Market Landscape (Additional Insight)* 12.1 Global Cancer Diagnostics: Developers Landscape 12.1.1 Analysis by Year of Establishment 12.1.2 Analysis by Company Size 12.1.3 Analysis by Region 12.2 Global Cancer Diagnostics: Product Landscape 12.2.1 Analysis by Product Type 12.2.2 Analysis by Technology 12.2.3 Analysis by Application

18. Disclaimer 05 01 This is a sample text. Trade Data Analysis Claight Corp. publishes market research reports on various industry verticals. All reports purchased via the website, email or over the phone are subject to the following disclaimer. A purchase automatically indicates acceptance of the disclaimer. We, at EMR, gather information from various sources such as face-to- face interviews, paid databases, annual reports, surveys and media releases. This information is collated in good faith and used on an as is and as available basis by us. Our reports should only be construed as guidance. We assert that any business or investment decisions should not be based purely on the information presented in our reports. We will not be responsible for any losses incurred by a client as a result of decisions made based on any information included in the reports. We do not guarantee or take responsibility for the accuracy, completeness, reliability and usefulness of any information. In many cases, the opinion expressed in the reports is our current opinion based on the prevailing market trends and is subject to change. The information provided by us is for the sole use of the authorised recipient(s). No part of the information or service may be duplicated or transmitted in any manner or by any medium without prior permission from EMR. Any such act will be considered as the breach of the ‘Terms & Conditions’ under which the report has been purchased.

19. Contact Us 05 01 This is a sample text. Trade Data Analysis https://www.expertmarketresearch.com https://www.linkedin.com/company/expert-market-research https://www.instagram.com/expertmarketresearch [email protected] https://x.com/expertmresearch https://www.facebook.com/expertmarketresearch https://www.youtube.com/c/Expertmarketresearch https://expertmarketresearch-emr.blogspot.com [phone]